- Home
- RM vs DBVT Comparison
RM vs DBVT Comparison
Compare RM & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RM
- DBVT
- Stock Information
- Founded
- RM 1987
- DBVT 2002
- Country
- RM United States
- DBVT France
- Employees
- RM N/A
- DBVT N/A
- Industry
- RM Finance: Consumer Services
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RM Finance
- DBVT Health Care
- Exchange
- RM Nasdaq
- DBVT Nasdaq
- Market Cap
- RM 282.1M
- DBVT 239.9M
- IPO Year
- RM 2012
- DBVT N/A
- Fundamental
- Price
- RM $26.06
- DBVT $8.11
- Analyst Decision
- RM Hold
- DBVT Buy
- Analyst Count
- RM 3
- DBVT 4
- Target Price
- RM $30.00
- DBVT $14.81
- AVG Volume (30 Days)
- RM 50.3K
- DBVT 102.2K
- Earning Date
- RM 07-30-2025
- DBVT 07-29-2025
- Dividend Yield
- RM 4.54%
- DBVT N/A
- EPS Growth
- RM 41.13
- DBVT N/A
- EPS
- RM 3.29
- DBVT N/A
- Revenue
- RM $577,647,000.00
- DBVT $3,497,000.00
- Revenue This Year
- RM $13.10
- DBVT $1,700.53
- Revenue Next Year
- RM $9.35
- DBVT $535.67
- P/E Ratio
- RM $8.03
- DBVT N/A
- Revenue Growth
- RM 6.45
- DBVT N/A
- 52 Week Low
- RM $25.41
- DBVT $2.21
- 52 Week High
- RM $37.52
- DBVT $12.78
- Technical
- Relative Strength Index (RSI)
- RM 33.92
- DBVT 41.18
- Support Level
- RM $26.16
- DBVT $8.33
- Resistance Level
- RM $27.01
- DBVT $9.92
- Average True Range (ATR)
- RM 0.71
- DBVT 0.86
- MACD
- RM -0.15
- DBVT -0.34
- Stochastic Oscillator
- RM 0.00
- DBVT 1.48
About RM Regional Management Corp.
Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. It is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.